Quantcast
Channel: WN.com - Articles related to Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia (Actelion Ltd)
Viewing all articles
Browse latest Browse all 480

Actelion to present at the 33rd J.P. Morgan Healthcare Conference - Transforming our PAH portfolio (Actelion Ltd)

$
0
0
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 12 January 2015- Actelion Ltd (SIX: ATLN) announced today that Jean-Paul Clozel, Chief Executive Officer of Actelion, will present at the J. P. Morgan Healthcare Conference on January 13, 2015 at 08:00 AM Pacific Standard Time / 17:00 Hrs Central European Time at the Westin St. Francis Hotel in San Francisco, CA. Dr. Clozel will describe the progress made during 2014 in delivering on Actelion's strategy for value creation, with a special focus on how the company is transforming its PAH portfolio. Jean-Paul Clozel, MD, Chief Executive Officer, commented: "I am looking forward to presenting our 2014 highlights with delivering on...

Viewing all articles
Browse latest Browse all 480

Trending Articles



<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>